Reply: Reduction in Risk of Disease Progression With Triple Therapy: Is it True for All?

TY - JOUR

T1 - Reply

T2 - Reduction in Risk of Disease Progression With Triple Therapy: Is it True for All?

AU - Chin, Kelly M.

AU - Doelberg, Martin

AU - Martin, Nicolas

AU - Perchenet, Loïc

AU - Galie, Nazzareno

N1 - Funding Information: This study was funded by Actelion Pharmaceuticals, Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson. Medical writing support was provided by Laura Corbett of eluSCIdate Ltd (Meggen, Switzerland) and was funded by Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson. Dr Chin has served as a steering committee member for Janssen Pharmaceutical Companies of Johnson & Johnson; has received research grants from Janssen Pharmaceutical Companies of Johnson & Johnson, the National Institutes of Health, Ironwood Pharmaceuticals, and SoniVie Ltd; has served on an advisory board for Bayer Healthcare (through UCSD) and Flowonix; has served as an adjudication committee member for Arena Pharmaceuticals; is Circulation associate editor for the American Heart Association; and has received consultancy fees from Janssen Pharmaceutical Companies of Johnson & Johnson. Drs Doelberg and Mr. Martin are employees of Actelion Pharmaceuticals Ltd. Dr Perchenet is an employee of and in the past has held stock/stock options for Actelion Pharmaceuticals Ltd; and currently holds stock/stock options in the parent company Johnson & Johnson. Prof Galie is a steering committee member for Janssen Pharmaceutical Companies of Johnson & Johnson; has received grant support and personal fees from Bayer Healthcare, Pfizer, GlaxoSmithKline, and Janssen Pharmaceutical Companies of Johnson & Johnson; and has received nonfinancial support from Janssen Pharmaceutical Companies of Johnson & Johnson. Funding Information: This study was funded by Actelion Pharmaceuticals, Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson. Medical writing support was provided by Laura Corbett of eluSCIdate Ltd (Meggen, Switzerland) and was funded by Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson. Dr Chin has served as a steering committee member for Janssen Pharmaceutical Companies of Johnson & Johnson; has received research grants from Janssen Pharmaceutical Companies of Johnson & Johnson, the National Institutes of Health, Ironwood Pharmaceuticals, and SoniVie Ltd; has served on an advisory board for Bayer Healthcare (through UCSD) and Flowonix; has served as an adjudication committee member for Arena Pharmaceuticals; is Circulation associate editor for the American Heart Association; and has received consultancy fees from Janssen Pharmaceutical Companies of Johnson & Johnson. Drs Doelberg and Mr. Martin are employees of Actelion Pharmaceuticals Ltd. Dr Perchenet is an employee of and in the past has held stock/stock options for Actelion Pharmaceuticals Ltd; and currently holds stock/stock options in the parent company Johnson & Johnson. Prof Galie is a steering committee member for Janssen Pharmaceutical Companies of Johnson & Johnson; has received grant support and personal fees from Bayer Healthcare, Pfizer, GlaxoSmithKline, and Janssen Pharmaceutical Companies of Johnson & Johnson; and has received nonfinancial support from Janssen Pharmaceutical Companies of Johnson & Johnson.

PY - 2022/2/22

Y1 - 2022/2/22

UR - http://www.scopus.com/inward/record.url?scp=85123983124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123983124&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2021.12.006

DO - 10.1016/j.jacc.2021.12.006

M3 - Letter

C2 - 35177202

AN - SCOPUS:85123983124

SN - 0735-1097

VL - 79

SP - e177

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 7

ER -